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Defensins represents an integral part of the innate immune system serving to ward off
potential pathogens and to protect the intestinal barrier from microbial encroachment.
In addition to their antimicrobial activities, defensins in general, and human β-defensin
2 (hBD2) in particular, also exhibit immunomodulatory capabilities. In this report, we
assessed the therapeutic efficacy of systemically administered recombinant hBD2 to
ameliorate intestinal inflammation in three distinct animal models of inflammatory bowel
disease; i.e., chemically induced mucosal injury (DSS), loss of mucosal tolerance (TNBS),
and T-cell transfer into immunodeficient recipient mice. Treatment efficacy was confirmed
in all tested models, where systemically administered hBD2 mitigated inflammation,
improved disease activity index, and hindered colitis-induced body weight loss on par
with anti-TNF-α and steroids. Treatment of lipopolysaccharide (LPS)-activated human
peripheral blood mononuclear cells with rhBD2 confirmed the immunomodulatory
capacity in the circulatory compartment. Subsequent analyzes revealed dendritic cells
(DCs) as the main target population. Suppression of LPS-induced inflammation was
dependent on chemokine receptor 2 (CCR2) expression. Mechanistically, hBD2 engaged
with CCR2 on its DC target cell to decrease NF-κB, and increase CREB phosphorylation,
hence curbing inflammation. To our knowledge, this is the first study showing in vivo
efficacy of a systemically administered defensin in experimental disease.
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INTRODUCTION
Inflammatory bowel diseases (IBD) are multifactorial disorders characterized by chronic relapsing
inflammation of the intestine (1). They currently affect more than 4 million patients worldwide (2)
and are classified in two major entities, Crohn’s disease (CD) and ulcerative colitis (UC). While UC
is mainly restricted to the colonic mucosa, CD can occur at any site of the gastrointestinal tract but
predominantly in the terminal ileum and colon, and inflammation is typically transmural (3).
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The etiology of the different forms of IBD is not fully
understood. It has, however, been demonstrated that differential
defects of the intestinal antimicrobial barrier play an important
role in the pathogenesis of both CD and UC (4). Genetic
analysis revealed that small intestinal vs. colonic CD are different
disease entities and are characterized by distinct but overlapping
genetic signatures (5). Moreover, in UC compromised mucus
production, due to depletion of goblet cells, is a key triggering
event in disease pathology, whereas CD is characterized by
a defective intestinal barrier, which associates with complex
defensin deficiencies based on a variety of mechanisms (6–10).
The best described genetic links to small intestinal CD (11), i.e.,
NOD2, ATG16L1, XBPD1, are functionally involved in Paneth
cell function (12–15). Paneth cells of the small intestine secrete
different antimicrobial peptides into the intestinal lumen. Other
mechanisms involving compromised α-defensin regulation of
Paneth cells include the Wnt signaling pathway (16). A reduced
monocyte derived Wnt ligand secretion in CD may further
diminish Paneth cells and defensin expression (10). In the colon,
we and others have shown an attenuated induction of the
inducible human β-defensin 2 (hBD2) in CD patients, although
the mechanisms remains elusive (7).
Defensins represent an ancient highly conserved part of
the innate immune system. Most of these small endogenous
peptides possess broad-spectrum antimicrobial activity as well
as immunomodulatory functions. In humans, granulocytes
as well as Paneth cells secrete different α-defensins whereas
β-defensins are expressed by epithelial surfaces throughout
the body (17). hBD2 was discovered using a functional
antimicrobial readout by Harder and Schröder in the skin
(18). As shown in vitro hBD2 has strong antimicrobial and
immunomodulatory functions and is induced by inflammatory
stimuli or exogenous microbial substances (19). hBD2
promotes intestinal wound healing (19) and angiogenesis
(20) in vitro and can act as a chemoattractant for dendritic cells
(DCs), monocytes and T-cells through interaction with the
chemokine receptor 2 (CCR2) and 6 (CCR6) (21, 22). Thus,
in addition to a lack of mucosal antibacterial activity (23) low
defensin expression may also translate into a repressed anti-
inflammatory activity. Together, these data provide evidence
for an important role of defensins, including hBD2, in IBD
disease pathogenesis and potential therapy, but its mode of
action in vivo and their potential role as therapeutics remains to
be described.
Standard therapy in IBD is based on immunosuppression
with glucocorticosteroids and azathioprine as short and long
term therapy, respectively. Antibodies that target tumor necrosis
factor alpha (TNFα) attenuate disease-related inflammatory
pathways rather than act as a general immunosuppressants,
but 20–40% of patients are primary TNFα non-responders and
up to 50% lose their effective response over time, termed
secondary non-responders (24, 25). Despite successful
development of other biologicals against specific targets
like integrins or IL-12/23, the medical need for alternative
therapeutic strategies targeting the molecular mechanisms
underlying IBD is still high, providing a sound rationale
for examining hBD2 as a potential biological therapy for
the treatment of IBD and potentially other barrier function
related inflammatory disorders. However, a major limitation
for considering development of hBD2 was the difficulty to
produce sufficient quantities of defensin peptides at industrial
scale. We have therefore developed a cost efficient large-scale
production method of recombinant hBD2 (26). In this study,
we hypothesized that hBD2 could act as an anti-inflammatory
peptide independently of its classical antimicrobial function.
We found that recombinant hBD2 suppressed DC-mediated
secretion of proinflammatory cytokines such as TNF-α, IL-
12 and IL-1β. The mechanism was dependent on CCR2
signaling leading to a reduced NF-κB but increased CREB
phosphorylation. Extending the in vitro findings, we next
assessed the capability of hBD2 to suppress IBD in three different
animal models of experimental colitis. We administered the
therapeutic agent by subcutaneous injections to uncouple its
classical antimicrobial actions from its immunomodulatory
capabilities. hBD2 administration significantly improved
the responding phenotype in both DSS-, TNBS-, and T-cell
induced colitis, hence corroborating broad treatment efficacy
in discrepant gastrointestinal disease pathologies. These data
represent the first in vivo evidence that a human defensin, such
as hBD2, offers a systemic, anti-inflammatory biologic agent,
which could be used as a promising future therapeutic against
human IBD.
MATERIALS AND METHODS
Human Blood Samples
In this study blood was obtained from healthy individuals (males
and females in 1:1 ratio) that gave their written and informed
consent after they were informed about the study purpose,
sample procedure, and potential adjunctive risks. The study
protocol was previously approved by the Ethical Committee of
the University Hospital, Tübingen, Germany and the Ethical
Committee of Region Capital, Denmark (Den Videnskabsetiske
komite Region Hovedstaden).
Production and Purification of
Recombinant hBD2
Recombinant hBD2 was expressed in E. coli as a his-tagged
thioredoxin fusion protein with an enterokinase cleavage site and
purified essentially as described in the patent (WO2010/007166
Treatment of inflammatory bowel diseases with human β-
defensin 2). An additional reversed phase purification step was
included to ensure removal of endotoxins. The processed and
purified hBD2 was diluted in water for injection supplemented
with 1% v/v formic acid and bound to a Daisogel SP-120-
C18 column and eluted with 1% v/v formic acid in 30%
v/v ethanol. The solvents were removed by evaporation in
a speed-vac and the final product formulated in PBS before
use. The proper folding and disulphide-bridge topology was
verified using tryptic digestion coupled with LC-MS/MS and
NMR spectroscopy. The purified hBD2 (endotoxin levels <
0.05 EU/ml) were kept in its natural tertiary structure with
purity ≥96%.
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In vitro Toxicity Tests
Red Blood Cell Assay
Blood was collected using EDTA as anticoagulant and diluted
in PBS to obtain an 8% red blood cell suspension. One part
of the red blood cell suspension was added to three parts of
test material (dissolved in PBS) in a poly propylene plate. One
percent sodium dodecyl sulfate (SDS) was used as a positive
control. Assay mixtures were incubated for 60min at 37◦C under
constant agitation of the plate. Incubation was terminated by
centrifugation at 2,000 rpm for 2–3min. 50µl of the supernatants
were transferred to a microtiter plate and measured at 540 nm.
Murine Fibroblasts L929 Neutral Red Uptake
Cytotoxicity was measured by the neutral red uptake procedure
of Borenfreund and Puerner, using mouse L929 fibroblasts
(ATCC R© CCL-1TM) and a 24 h exposure to hBD2 (27). L929
fibroblasts were grown in EMEM supplemented with 10% fetal
bovine serum (FBS). For testing 7.5 × 104 cells were seeded into
96 well plates and incubated for 24 h at 37◦C to establish a near
confluent monolayer. Cells were challenged with the indicated
concentrations of hBD2, SDS was used as control.
In vivo Toxicity Test
In vivo toxicity of hBD2 was assessed in 6–8 weeks old female
NMRImice (Taconic Europe). All animal studies were performed
according to Danish legislations for laboratory animals and
approved by Novozymes science ethics committee. hBD2 was
given subcutaneously (s.c.) in the intrascapular region using a
25G needle and a 1ml syringe. Animals were dosed on day 0 with
the indicated amount of hBD2, applied as 10 mg/kg according
to the individual body weight. Clinical signs were recorded on
day 0 and monitored until experimental endpoints. Body weights
were recorded as a minimum on day 0, day 2, and day 4 prior
to euthanasia. Necropsy was performed after euthanasia and
kidneys, spleens and livers were weighed.
Pharmacokinetic Profile of hBD2
Two groups of female NMRI mice were weighed and injected s.c.
with either 1mg/kg (n= 4) or 10 mg/kg (n= 3) hBD2 in 300 µl.
HBD2 was diluted in 10mM sodium acetate in 0.9% NaCl. Blood
samples were collected at different time points and stored at room
temperature for a minimum of 20min before centrifugation at
2,000 × g for 10min. Serum was separated and stored at −20◦C
until analysis. Serum from the group that received 10 mg/kg was
analyzed by LC-MS/MS, the serum from the other group was
analyzed by HPLC.
Stimulation of Peripheral Blood
Mononuclear Cells (PBMCs)
Heparinized blood was diluted 1/1 v/v with RPMI (Gibco)
and was subjected to Ficoll-Paque Plus (GE healthcare) density
centrifugation within 2 h of drawing. Plasma was collected from
the top from individual donors and was kept on ice until it
was used at 2% in the culture medium (autologous culture
medium). Isolated PBMC’s were re-suspended in autologous
culture medium and seeded in 96-well culture plates with
115.500 cells per well (Figure 1) or 200.000 cells per well
(Figure 2) in a total of 200µl. PBMC’s from the same
donor were stimulated with 100, 10 or 1µg/ml of hBD2
either alone or together with 20 pg/ml lipopolysaccharide
(LPS) (E. coli, O111:B4, Sigma L4391) or with 0.3µg/ml
Pam3CSK4 (InvivoGen). The supernatants were collected after
incubation at 37◦C for 24 h, and stored at −80◦C until
cytokine measurement.
The experiment in Figure 1 was performed with healthy
volunteers, which were recruited under an approval from the
Ethical Committee for Region Capital, Denmark. Interleukin
1β (IL-1β) and tumor necrosis factor alpha (TNF-α) (Figure 1)
were quantified in supernatants by flow cytometry using a
human inflammation cytometric bead array (CBA) according
to manufacturer’s instructions (BD) using a FACSarray flow
FIGURE 1 | hBD2 reduced the pro-inflammatory effect of LPS and Pam3CSK4 in human primary PBMC’s. PBMC’s were challenged with LPS (20 pg/ml) or
Pam3CSK4 (0.3µg/ml), respectively, and treated with various concentrations of hBD2 (100, 40, 10, or 1µg/ml). Release of (A) IL-1β and (B) TNF-α. Results are
presented as mean ± SEM, (A) and (B) n = 150–194. Statistical analysis was performed by one-way ANOVA with Bonferroni post-test.
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FIGURE 2 | hBD2 reduced the pro-inflammatory effect of LPS in human primary PBMC’s of ulcerative colitis patients. PBMC’s were challenged with LPS (20 pg/ml)
and treated with 10µg/mL hBD2. Release of of (A) IL-1β, (B) TNF-α, (C) INF-y, (D) IL-23, and (E) IL-12p70 is shown in % normalized to LPS. Data are presented as
mean ± SEM (n = 4) and analyzed by unpaired t-test.
cytometer. IL-1β, TNF- α, Interferon gamma (INF-y), Interleukin
12p70 (IL-12), and Interleukin 23 (IL-23) were analyzed using
a human inflammation cytometric bead array (LegendPlex
Biolegends) according to manufacturer’s instructions.
The experiment in Figure 2 was performed with
8 subjects (4 controls and 4 colitis patients) to study
the impact of disease status on treatment efficacy.
Clinical status of these subjects were subtotal remission
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(Simponi and Salofalk), remission (Vedolizumab), mild
disease (Infliximab, Salofalk, and Prednisolon), and
moderate disease (Vedolizumab). PBMCs from these
subjects were analyzed for IL-1b, TNF-a, IFN-g, IL-
12, and IL-23 expression using a human inflammation
cytometric bead array (LegendPlex Biolegends) according
to manufacturer’s instructions.
Generation of Human Monocyte-Derived
Dendritic Cells (Mo-DCs)
Peripheral blood was drawn from healthy donors and diluted
one to one in PBS. The mixture was stacked in a falcon
tube on Biocoll separation solution (Biochrome) with a
ratio of three parts blood PBS mixture to two parts Biocoll.
For a density gradient centrifugation the falcon tubes were
centrifuged at 2,000 rpm for 30min at RT. The PBMC’s
were removed and washed twice with PBS. 1.5 × 106 cells
were seeded per well in a tissue culture-treated 6-well plate
in RPMI-1640 medium (Merck) supplemented with 10%
fetal calf serum (FCS; Sigma-Aldrich), 2mM L-glutamine
(Biochrome), 100 U/ml penicillin/streptomycin (Gibco),
50µM 2-mercaptoethanol (Fluka), 1mM sodium pyruvate
(Biochrome), and 1x non-essential amino acids (Biochrome)
and incubated for 1 h at 37◦C and 5% CO2 for monocyte
adherence. Then the cells were washed with media and PBS to
remove the non-adherent cells and were cultivated for 6 days
with media additional supplemented with 50 ng IL-4 and 100
ng GM-CSF (Miltenyi). Cytokines were added a second and
third time on day 2 and 4 whereas the cells were harvested
at day 6.
Generation of Bone Marrow-Derived
Dendritic Cells (BM-DCs)
BM-DC’s were generated using granulocyte-macrophage
colony-stimulating factor (GM-CSF) and RPMI-1640 medium
(Merck) supplemented with 10% fetal calf serum (FBS; Life
Technologies), 2mM glutamine (Thermo Fisher), 100 U/ml
penicillin/streptomycin (Gibco), 50µM 2-mercaptoethanol
(Roth), 1mM sodium pyruvate (Biochrome), and 1x
non-essential amino acids (Biochrome) as previously
described (28). Shortly, 2 × 106 bone marrow cells
flushed from the tibias and femurs of C57BL/6 mice
were seeded in dishes containing 200 U/ml GM-CSF.
After 3 days extra medium containing GM-CSF was
added to the cells and on day 6 half of the medium was
replaced by fresh serum containing GM-CSF. After 7
or 8 days slightly attached cells were harvested. Female
C57BL/6JolaHsd mice were purchased from Janvier (St.
Berthevin Cedex, France). Animal experiments were
performed in strict accordance with the German regulations
of the Society for Laboratory Animal Science (GV-
SOLAS) and the European Health Law of the Federation
of Laboratory Animal Science Associations (FELASA).
The protocol was approved by the Regierungspräsidium
Tübingen (Anzeige 09.01.2014).
Cytokine Production by Human Mo-DC’s
and Murine BM-DC’s
2 × 105 murine BM-DC’s or human Mo-DC’s were seeded
in 96-well round bottom plates. First they were pretreated
with 100 ng/ml pertussis toxin (Sigma-Aldrich) or 5µM of
the CCR2 inhibitor RS 504393 (Tocris) and subsequently
stimulated with 100 ng/ml LPS or 0.2 mg/ml TNF-α, 0.2
mg/ml IL-6 and 0.2 mg/ml IL-1β and 10µg/ml or 100µg/ml
hBD2. 24 h later supernatants were collected and TNF-α
[Biolegend (BM-DC’s); R&D (Mo-DC’s)] was analyzed according
to the manufacturer’s instructions. IL-10, IL-12, and IL-1β
(LEGENDplex Biolegend) was as well-analyzed according to the
manufacturer’s instructions.
Flow Cytometry
2 × 105 murine BM-DC’s were seeded in 96-well round bottom
plates and treated as described above. Cells were removed
from the plate using Accutase (Sigma-Aldrich) and stained for
20min at room temperature with Zombie Aqua (Biolegend) to
exclude dead cells and extracellular antibodies against CD11c-
APC (N418) (Miltenyi), MHCII-FITC (M5/114.15.2) (Miltenyi)
and CD86-BV421 (GL-1) (Biolegend). For p-CREB staining
cells were fixed and permeabilized with Foxp3 Staining Buffer
Set (eBioscience) and stained with primary antibody phosphor-
CREB mAb (Ser133; clone 87G3) (Cell Signaling) for 30min in
the dark at room temperature followed by secondary goat anti-
rabbit IgG-DyLightTM649 (Jackson ImmunoResearch) for 15min
at 4◦C. To detect intracellular p-NF-κB BM-DCs were fixed with
2% paraformaldehyde (VWR) in PBS, permeabilized with 90%
freezing methanol (Applichem) and stained with the primary
antibodies to phosphor-NF-κB p65 (93H1) (Cell Signaling) for
60min in the dark at room temperature followed by goat anti-
rabbit IgG-PE-Cy7 (Santa Cruz Biotechnology) for 15min at 4◦C.
PBS with 0,5% bovine serum albumin (Biomol) was used for all
incubations and washing steps. At least 50,000 cells were acquired
using a Canto-II flow cytometer (BD nces) with DIVA software
(BD Biosciences) and were further analyzed using FlowJo 10.5
software (Tree Star).
DSS Colitis Model
The DSS colitis study was performed by Farma-Cros Ibérica
according to directive 86/609 EEC and approved by Novozymes
science ethics committee. 7–8 weeks oldmale C57BL/6mice were
used (Charles River) and each group consisted of 10 animals.
Animal allocation to all experimental groups was done in a
randomized manner. Colitis was induced by supplementing the
drinking water with 2% dextran sodium sulfate (DSS, 30–50 kDA,
MP Biomedicals) for 7 days. On day 1 all mice were weighed
and the drinking bottle was filled with the DSS solution, this
solution was replaced on day 3 and 5. On day 8 the remaining
solution was discarded and replaced with autoclaved water. Mice
were divided into 3 groups. One group received PBS as sham
treatment intravenously. One group received on day 1, 4, and 8,
300µg/mouse of a mouse anti-TNF-α antibody (αTNF, Ramcon)
intraperitoneally. The animals in the other group were dosed s.c.
with 0.1 mg/kg hBD2 once a day, starting at day 1 until day 10.
Animals were euthenized on day 10. Daily clinical assessment was
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carried out to calculate a validated clinical disease activity index
(DAI) ranging from 0 to 4 according to the following parameters:
body weight loss, presence or absence of rectal bleeding, stool
consistency. One mouse in the DSS control group had to be
euthanized before the end of the study.
TNBS Colitis Model
The TNBS colitis study was performed by Farma-Cros
Ibérica according to directive 86/609 EEC and approved by
Novozymes science ethics committee. Male BALB/cByJ mice
were used (Janvier) and each group consisted of 15 animals.
Animal allocation to all experimental groups was done in
a randomized manner. Colitis was induced on day 0 by
intracolonic (distal) administration of trinitrobenzene sulfonic
acid (TNBS), 1 mg/mouse in 50% ethanol under mild anesthesia
(ketamine/xylazine). Treatment of the animals started on day 0
after induction of colitis. All compounds were applied s.c. Mice
received PBS (TNBS control), Prednisolone (10 mg/kg), or hBD2
0.1 mg/kg), respectively. In the TNBS control group as well as
in the Prednisolone group, 2 animals had to be sacrificed before
the end of the experiment. All other animals were sacrificed on
day 10. Daily clinical assessment was carried out to calculate
a validated clinical DAI ranging from 0 to 4 according to the
following parameters: body weight loss, presence or absence of
rectal bleeding, stool consistency.
T Cell Colitis Model
This study was performed by the Department of Biomedical
Science at the University of Catania according to directive 86/609
EEC and approved by Novozymes science ethics committee. 8
weeks old female BALB/c and C.B-17 female SCID mice were
purchased from Harlan (Italy). Colitis was induced in severe
combined immunodeficiency (SCID) mice by transplantation
of CD4+/CD25− T cells from the BALB/c mice. Briefly,
lymphomonocytes isolated from spleen or lymph nodes from
BALB/c mice were subjected to negative selection of CD4+ T
cells. Afterwards, CD4+/CD25+ cells were positively isolated by
binding to the beads from the CD4+ T cell suspensions and the
CD4+/CD25− were collected from supernatant. Cell preparation
was considered successful if the analysis of purified cells by flow
cytometry (FACSCalibur, BD Bioscience, Heidelberg, Germany)
using CellQuest software showed that >95% of the cells
were viable (based on forward and side-scatter characteristics
and/or 7- actynomycin-D staining) and CD4-positive (using
a FITC-conjugated anti-mouse CD4-antibody, BD, Heidelberg,
Germany), as well as more than 98% depleted of CD25 (using
a APC-conjugated anti-mouse CD25-antibody, BD, Heidelberg,
Germany). CD4+/CD25− cells were intraperitoneally injected to
SCIDmice at a concentration of 500,000 cells in a final volume of
0.2ml RPMI 1640. Sham treated animals (n = 6) received 0.2ml
pure RPMI 1640. Diseased mice were randomized divided into
4 groups (n = 11) and treated once daily by s.c. application of
PBS (vehicle), hBD2 (0.1 and 1 mg/kg, respectively) or 0.3 mg/kg
Dexamethasone (Dexa., applied intraperitoneally). Treatments
started 7 days post T cell transfer and continued daily for 86 days.
Animals were weighed three times a week and monitored twice a
week starting from day 42 for the clinical status, summarized as
DAI. The DAI included body weight loss, stool consistency, and
the presence of blood at the rectum. One animal in the vehicle
and one in the Dexamethasone treated groups had to be sacrificed
before the end of the study. At the end of the study, animals
were sacrificed and the colon was removed and carefully cleaned
for further analysis. First, the colon was weighed then a section
from the middle was removed and fixed for pathologic survey.
The rest of the colon (5 cm) was used to quantify the activity of
myeloperoxidase in the tissue.
Myeloperoxidase Activity Assay
Myeloperoxidase activity was performed on 5 cm of colon
previously frozen at −80◦C. Colon was homogenized in 0.5%
of HETAB dissolved in 10mM of Phosphate-Citrate Buffer
(pH 7.0) to enable the release of MPO enzyme from the
neutrophil granules. Homogenated samples after three freeze-
thaw cycles were spun at 3,000 × g at 4◦C for 30min. Pellets
were resuspended in 0.5% HETAB in 10mM Phosphate-Citrate
Buffer and spun again at 3,000 × g at 4◦C for 30min. 500
ul of supernatant were delivered into a vial along with 500
ul of TMB in Phosphate-Citrate Buffer containing Perborate
Sodium. Changes in absorbance at 620 and 450 nm were read by
a spectrophotometer (IRIS). Peroxidase enzyme diluted in 0.5%
HETAB in 10mM Phosphate-Citrate Buffer and H2O was used
as standard. Two-fold dilutions of standard were prepared at the
highest concentration of 50 pg/ml. Reagents and samples were
kept refrigerated. Substrate solution was prepared just before the
assay. MPO activity expresses the amount of enzyme that is able
to degrade 1µM of peroxide/min and it is expressed as U/g
tissue weight.
Preparation of Histological Samples
Sections of the colon were taken from each animal and preserved
in neutral buffered formaline for subsequent histological analysis.
Sections were stained using haematoxylin and eosin for
further scoring.
Statistical Analysis
Release of cytokines from PBMC’s was compared using two-
way ANOVA and Tukey post-test or unpaired student’s t-test
as appropriate. Weight change, colon weight and MPO activity
were compared using one-way-ANOVA and Bonferroni post-
test, while clinical and pathological scores were analyzed by a
Kruskal-Wallis-test for non-parametric data with a Dunn’s post-
test. All statistical analyses and graphs were done using GraphPad
Prism 8 (GraphPad Software, USA).
RESULTS
hBD2 Modulated the Effects of Toll-Like
Receptor Ligands in PBMC’s
We selected human PBMCs challenged with LPS as an ex vivo
read out model to assess the anti-inflammatory potential
of hBD2. While LPS-challenged PBMCs secreted ample
amount of interleukin 1-β (IL-1β) (Figure 1A) and TNF-α
(Figure 1B), co-treatment with increasing doses of hBD2
consistently mitigated release of both cytokines. hBD2 is a
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positively charged peptide and could potentially bind to the
negatively charged LPS, hence mediate the observed effect
indirectly without interfering with the pathway. To investigate
this possibility, we included an alternative toll like receptor
(TLR) ligand, Pam3CSK4; a neutral/negative charged synthetic
peptide. As shown in Figure 1, hBD2 significantly reduced the
Pam3CSK4 induced release of IL-1β and TNF-α, corroborating
a strong anti-inflammatory effect of hBD2 on human
PBMCs ex vivo.
We next evaluated if the immune modulating capabilities of
hBD2 could be extended to colitis patients. This patient group
is known to exhibit an altered response to immunomodulatory
stimuli compared to healthy controls. We therefore expanded
the proinflammatory panel to also include interferon (INF)-γ,
IL-12p70, and IL-23. Despite the low n-size in this proof-of-
concept sub-experiment, hBD2 treatment successfully attenuated
the proinflammatory immune response in LPS-stimulated
PBMCs (Figure 2).
Cytokine Production of DC’s Was Affected
by hBD2 in a TLR- and CCR2-Dependent
Manner
Since PBMCs comprise a variety of cell types we aimed to
characterize the responsive cell type, and furthermore the
receptor that was targeted by hBD2. DCs upregulate cytokine
production when their TLRs engage their cognate ligands (29).
Thus, we hypothesized that DC mediated cytokine secretion was
affected by hBD2. We generated human mo-DCs and murine
BM-DCs in vitro, and subsequently challenged them with LPS
with or without two different concentrations of hBD2. Similar
to the previously reported PBMC response (Figures 1, 2), hBD2
treatment dose-dependently curbed TNF-α production in LPS-
challenged DCs (Figures 3A,B).
To test whether the hBD2-mediated cytokine modulation was
restricted to TLR signaling, we next investigated the cytokine
production of BM-DCs stimulated with a TLR-independent
cytokine cocktail. While hBD2 treatment alleviated LPS-induced
TNF-α, IL-12p70, and IL-1β secretion concomitant with a
substantial induction of the anti-inflammatory cytokine, IL-10,
same treatment failed to modulate TLR-independent activation
of BM-DCs (Figures 3C,D and Figures S1B,C).
Since hBD2 is able to bind to G protein-coupled receptors
expressed on monocytes and DCs (22), we pretreated BM-
DCs with pertussis toxin prior to the stimulation with LPS
and hBD2. Inhibition of G protein-coupled receptor signaling
prevented the observed immunomodulatory capacity of hBD2.
Thus, BM-DCs pre-treated with pertussis toxin and stimulated
with LPS and hBD2 showed similar TNF-α, IL-1β, IL-10, and IL-
12p70 secretion compared to BM-DCs treated solely with LPS
(Figures 3E,F and Figures S1D,E).
To specify the G protein-coupled receptor interaction of
hBD2 we pre-treated BM-DCs with the CCR2 specific inhibitor,
RS504393, and subsequently stimulated with LPS and hBD2. Pre-
treatment with RS504393 prevented the anti-inflammatory effect
of hBD2 (Figures 3G,H and Figures S1F,G). Together these data
demonstrate a central involvement of CCR2 in hBD2-mediated
DC cytokine modulation; a trait that was shared between human
(Figure S1A) and mouse DCs.
hBD2 Modulates NF- κB and CREB
Phosphorylation
NF-κB represents a key signaling pathway triggered by TLRs.
This pathway can also be activated by the proinflammatory
cytokines TNF-α and IL-1β (30). NF-κB activity is mediated
by direct interaction with the CREB coactivator CBP. However,
phosphorylated CREB, that can be induced by G protein-
coupled receptors, needs in addition CBP to compete with NF-
κB and thereby limiting the NF-κB activity (31). We analyzed
the NF-κB and CREB phosphorylation of hBD2 treated BM-
DCs. Stimulation with proinflammatory cytokines showed an
increase in NF-κB phosphorylation although to a lower extent
than what was observed during LPS stimulation. Co-incubation
of both stimuli with hBD2 showed only a reduced NF-κB
phosphorylation when BM-DCs were treated with the TLR
ligand LPS in combination with hBD2 (Figures 4A,I). However,
pre-treatment with the CCR2 inhibitor RS504393 prior to
stimulation showed comparable levels of NF-κB phosphorylation
irrespective of hBD2 treatment (Figures 4B,I). CCR2 inhibition
therefore prevented the hBD2-mediated reductions in NF-κB
activation. Although the mechanism behind this observation
remains elusive, LPS-challenged BM-DCs showed reduced
maturation status when stimulated with hBD2, corroborated
by lower levels of their key activation markers, MHCII and
CD86 (Figures 4C,E). Again, pre-treatment with the CCR2
inhibitor prevented this lower expression (Figures 4D,F). We
hypothesized that the CREB signaling pathway could counter
NF-κB phosphorylation. We therefore analyzed the CREB
phosphorylation status in a next step of experiments. We
demonstrated that triggering G protein-coupled receptors
led to an increase in CREB phosphorylation (Figures 4G,I)
and simultaneously to a reduced NF-κB phosphorylation
(Figure 4A), suggesting that phosphorylated CREB competes
with NF-κB for their mutual cofactor, CBP. In contrast, pre-
treatment with the CCR2 inhibitor prevented the increase in
CREB phosphorylation (Figures 4H,I).
Recombinant hBD2 Showed Good
Tolerability and Rapidly Entered the
Bloodstream After Subcutaneous
Administration, Hence Allowing Systemic
Immunomodulatory Actions
To identify possible toxicity of recombinant expressed hBD2
we first addressed the hemolytic potential of hBD2 on human
red blood cells. As shown in Figure S2A we could not detect
any hemolytic effect of ≤300µg/ml hBD2. We next tested the
effect on the viability of murine fibroblasts. No negative effect of
hBD2 up to a concentration of 1750µg/ml could be identified
(Figure S2B). Combined, these data corroborates high in vitro
tolerability. To assess hBD2 toxicity in vivo, NMRI mice were
challenged s.c. with different doses of hBD2 and monitored for
4 days for the development of clinical symptoms. On day 4,
mice were euthanized for necropsy. Table 1 records the clinical
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FIGURE 3 | Cytokine production of DC’s was affected by hBD2 in a TLR- and CCR2-dependent manner. Human mo-DC’s and murine BM-DC’s were treated with
LPS (10µg/ml) alone or co-incubated with various concentrations of hBD2 (100µg/ml or 10µg/ml). Murine BM-DCs were additionally treated with pertussis toxin or
the CCR2 inhibitor RS prior to stimulation with LPS or a cytokine cocktail containing TNF-α (0.2 mg/ml), IL-6 (0.2 mg/ml), and IL-1β (0.2 mg/ml). Release of TNF-α in
(A) human Mo-DC’s and in (B) murine BM-DC’s was quantified by ELISA. Release of TNF-α (C,E,G) and IL-10 (D,F,H) in murine BM-DCs was quantified by
LEGENDplex. Results are presented as mean ± SEM, n = 3. Statistical test used is one-way ANOVA with Bonferroni post-test.
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FIGURE 4 | hBD2 modulates NF-κB and CREB phosphorylation. BM-DC’s were incubated for 60min with LPS (10µg/ml) or a cytokine cocktail containing TNF-α
(0.2mg/ml), IL-6 (0.2mg/ml), and IL-1β (0.2mg/ml) alone or in combination with hBD2 (100µg/ml). BM-DCs were additionally pretreated with pertussis toxin or the
CCR2 inhibitor RS prior to stimulation. The cells were stained with CD11c, MHCII, and CD86 antibodies followed by intracellular staining against p-NF-κB or p-CREB
and analysis by flow cytometry. Statistical analysis of (A,B) p-NF-κB, (C,D) MHCII, (E,F) CD86, and (G,H) p-CREB staining. (I) Shows histograms of FACS analysis.
Results are presented as mean ± SEM, n = 6. Statistical test used is one-way ANOVA with Bonferroni post-test.
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TABLE 1 | Clinical symptoms after subcutaneous administration of hBD2.
Test
compound
Dose level
mg/kg
Clinical signs on the day of dosing Necropsy
No clinical
signs
Pruritus Clinical
signs
Clinical signs at the end of
the day of dosing
Macroscopic
findings
Vehicle 0 3/3 0/3 0/3 0/3 0/3
HBD2 0.5 3/3 0/3 0/3 0/3 0/3
10 0/3 3/3 3/3 0/3 0/3
40 0/3 3/3 3(severe)/3 0/3 0/3
symptoms observed. Althoughminor acute effects were observed
(minutes), no adverse effects were observed at necropsy. Shortly
after challenge (10–15min) the mice receiving 10 or 40 mg/kg
hBD2 showed mild clinical signs such as decreased locomotor
activity, proneness, ptosis, piloerection, pruritus, bradypnoea,
reddish discoloration around the eyes and swelling around the
eyes and snout. All clinical signs were transient and only mice
dosed with 40 mg/kg hBD2 were still affected at 60min post
dosing. Of note, 40 mg/kg is 40 times higher than the highest
dose used in our in vivo experiments. The lowest dose group, 0.5
mg/kg hBD2 and the vehicle group did not develop any clinical
signs after systemic challenge. No further clinical signs were
observed during the subsequent 4 day observation period nor
could we find any abnormalities during necropsy. Additionally,
body weight gain and organ weight were recorded. Mice did not
show any weight loss nor did the organ weight differ significantly
between the groups (Figures S2C,D). In summary, these results
indicate that hBD2 is well-tolerated in vivo.
We next analyzed whether s.c. administered hBD2 would
enter the blood stream. For that purpose we injected mice s.c.
with 1 or 10 mg/kg hBD2 and quantified the amount of hBD2
in serum at different time points after injection. As shown in
Figure S2E, hBD2 entered the blood stream rapidly after s.c.
injection and remained detectable for more than 2 h. These
findings indicate that s.c. applied hBD2might not only act locally
but could also have systemic effects in vivo.
hBD2 Ameliorated the Outcome of DSS
Colitis in vivo
The above described results prompted us to investigate the
clinical potential of hBD2 using murine models of experimental
colitis with different disease pathologies. First, we assessed the
anti-inflammatory and protective effect of hBD2 in DSS colitis.
DSS causes a chemical injury to the intestinal mucosa. This
results in the exposure of the lamina propria and submucosal
compartments to luminal antigens and enteric bacteria which
results in inflammation and ulcer formation (32). Treatment of
DSS colitis with s.c. administered hBD2 (0.1 mg/kg) resulted in
a significant improvement of colitis; the therapeutic effect was
superior to anti-TNF-α treatment (Figure 5). hBD2 prevented
excessive weight loss (Figure 5A) and improved the DAI
(Figure 4B). Furthermore, scoring of the colonic mucosa for
damage revealed a significantly reduced mucosal damage in mice
treated with hBD2 (Figure 5C). Histological assessment of colon
(Figure 5D) showed strong mucosal damage caused by DSS,
characterized by a massive loss of the crypt architecture. In
contrast, treatment with hBD2 prevented this loss of crypts and
maintained a normal mucosa, comparable to the naïve mice.
hBD2 Significantly Improved TNBS Colitis
in vivo
We next tested the efficacy of hBD2 in TNBS induced colitis.
TNBS reacts with proteins in the colon (haptenation), thus
making them immunogenic. TNBS is dissolved in ethanol, which
permeabilizes the colonic epithelium. The immunogenic proteins
then cause a predominantly Th1 type response restricted to
the colon (33). In contrast to DSS colitis, TNBS colitis did
not result in weight loss, but rather prevented weight-gain in
mice during the time of our experiment. Weight changes were
similar between groups, although hBD2 treated mice trended
toward increased weight gain from day 1–7 (Figure 6A). Yet,
s.c. treatment with 0.1 mg/kg hBD2 significantly reduced colon
weight and a similar tendency was also observed for prednisolone
(Figure 6B), indicating a reduced infiltration of inflammatory
cells. Finally, s.c. treatment with hBD2 significantly improved
the macroscopic (Figure 6C) as well as the microscopic score
of mouse colons (Figures 6D,E) comparable with the effect of
prednisolone. Microscopic analysis of the colon showed a loss of
crypts in diseased mice, while mice receiving 0.1 mg/kg hBD2
showed a nearly normal mucosa comparable to prednisolone
treated mice.
Protective Effect of hBD2 in T Cell Transfer
Colitis
Finally, we tested hBD2 in a model of T cell transfer colitis.
In this model CD4+ T cells from immunocompetent mice are
adoptively transferred into severe combined immunodeficiency
(SCID) mice, lacking T cells. The transferred T cells respond
to enteric bacteria with the release of IL-2 and INF-γ
(34). The inflammation is restricted to the colon, and
extends diffusely from the cecum to the rectum. Besides
affecting the lamina propria, the pathogenesis can also be
transmural (35). Importantly, in addition to the different disease
pathology, this model also results in chronic inflammation
as oppose to the acute models (DSS and TNBS) previously
examined. Colitis was induced in SCID mice by transferring
CD4+/CD25− T cells from WT mice. One group of SCID
mice did not receive a T cell transfer (naive). Mice that
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FIGURE 5 | hBD2 ameliorated the outcome of DSS colitis in vivo. Colitis was induced by adding 2% DSS into the drinking water. On day 8 DSS was removed from
the drinking water. Mice were treated either once a day s.c. with 0.1 mg/kg hBD2 or intraperitoneally with an anti-TNFα antibody (300 µg/mouse) on day 1, 4, and 8.
(A) Weight change of mice during the experiment, (B) development of DAI, (C) histology score from the colon of the mice at the end of the experiment, and (D)
representative images from the colon of differentially treated mice. Results are presented as mean ± SEM, control group n = 9 and treated groups n = 10.
Appropriate statistical comparison are shown within the graph by a Kruskal-Wallis-test for non-parametric data with a Dunn’s post-test.
received a T cell transfer gained significantly less weight
than naive mice. Based on the chronic nature of this
model and the involvement of numerous cell type of the
immunological arsenal, we applied two different doses of
hBD2 to increase the therapeutic window. Colitis mice
treated with 1 mg/kg hBD2 s.c. showed less weight loss
(Figure 7A) and demonstrated an improved DAI (Figure 7B)
in comparison to the T cell colitis control group. Same
trait was observed for the stool score (Figure 7C). The
increased scores in the untreated colitis group appeared earlier
than in the hBD2 treated group indicating a protective
effect of hBD2. Furthermore, treatment with 1 mg/kg hBD2
significantly reduced the colon weight (Figure 7D) supporting
the conclusion of mitigated inflammation. Only a minor
effect of hBD2 on colonic myeloperoxidase activity could be
observed (Figure 7E). Histological analysis (Figure 7F) showed
pronounced inflammation in colitis mice without treatment,
while mice treated with 1 mg/kg hBD2 showed less signs of
inflammation and tissue disruption. Less signs of inflammation
were also observed in the colon of dexamethasone treated mice.
Furthermore, dexamethasone also improved DAI, stool score
and colon weight significantly and was therefore superior to
hBD2 in the T cell transfer model. The high dose of hBD2
(one log higher than previous experiments) seemed essential as
0.1 mg/kg hBD2 did not improve the outcome of T cell mediated
colitis (Figures 7A–F).
DISCUSSION
Herein we report that hBD2 can be used as a systemically
administered anti-inflammatory biological. hBD2 is well-
tolerated, both in vitro, and in vivo. These observations are
in line with published in vitro studies testing hBD2 with
human mesenchymal stem cells, osteoblasts, keratinocytes,
and HeLa cells without observing cytotoxic effects (36). Otte
et al. (19) additionally found that hBD2 was well-tolerated
by intestinal epithelial cells. Of note and in contrast to
hBD2, high concentrations of hBD3 demonstrated cytotoxic
effects in human dendritic cells and keratinocytes (37). After
subcutaneous injection we observed a dose dependent pruritus
of short duration which only occurred at doses magnitudes
higher than the later identified therapeutic doses. At all doses
(up to 40 mg/kg), body weight and organ weights of liver, spleen
and kidney were unaffected.
Peak hBD2 drug serum concentrations were also dose
dependent and in the range of 2–10µg/ml after single doses of
1 vs. 10 mg/kg. Using medium concentrations in a similar range
we confirmed that hBD2 attenuates inflammatory responses
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FIGURE 6 | hBD2 significantly improved TNBS colitis in vivo. Colitis was induced by a single dose of TNBS into the colon. Mice were then treated s.c. with different
doses of hBD2 (0.1 mg/kg) or Prednisolone (10 mg/kg) once a day and monitored for 7 days. (A) Development of mouse weight during the experiment. After
euthanization, the colon of the mice was examined for (B) colon weight, (C) macroscopic abnormalities, and (D) microscopic evidence of inflammation. (E)
Representative images from the colon of differentially treated mice are shown. Results are presented as mean ± SEM, control group n = 14, prednisolone group
n = 14, and hBD2 group n = 15. Appropriate statistical comparisons are shown within the graph by a Kruskal-Wallis-test for non-parametric data with a Dunn’s
post-test.
of human PBMC’s in vitro. TNF-α, IL-1β, and IL-12p70 were
consistently reduced after hBD2 treatment, whereas the anti-
inflammatory cytokine, IL-10, was significantly increased. TNF-
α is a well-known key inflammatory mediator of IBD and a
successful target of modern biologicals in the treatment of IBD
and other inflammatory diseases (38). In addition, IL-1β has
recently been described to mediate intestinal inflammation in
IBD patients with IL-10 receptor deficiency, and is thus proposed
as a potential therapeutic target (39). In a follow-up pilot study
using 4 colitis patients and 4 healthy controls, we confirmed the
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FIGURE 7 | Protective effect of hBD2 in T cell transfer colitis. Colitis was induced by transferring CD4+/CD25− T cells from WT mice to SCID mice. Development of
colitis was observed for 94 days. Daily treatment with hBD2 (0.1 mg/kg or 1 mg/kg, s.c.) and Dexamethasone (0.3 mg/kg, i.p.) started 7 days after the transfer.
(A) Weight change of mice during the experiment was monitored as well as (B) development of clinical symptoms as DAI. (C) Alteration of stool consistency was
assessed as stool score. At the end of the experiment (D) colon weight was measured and (E) activity of myeloperoxidase (MPO) was quantified. (F) Representative
images from the colon of differentially treated mice are shown. Results are presented as mean ± SEM, n = 6 (sham treated animals), n = 10 (vehicle and
dexamethasone mice) and n = 11 (hBD2 mice). Appropriate statistical comparisons are shown within the graph by a Kruskal-Wallis-test for non-parametric data with
a Dunn’s post-test.
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immunomodulatory capabilities of hBD2 in both groups, lending
further credence to the hypothesis that hBD2 might be used as a
novel biological to either treat colitis patients or alternatively to
keep such patients in remission.
In a next step, we identified DCs as one cell population
amongst PBMCs whose cytokine secretion is modulated by
hBD2. Because it is already known that hBD2 is able to induce
chemotaxis by binding to the CCR2 receptor (22), we investigated
whether the observed hBD2 mediated downregulation of
inflammation might depend on CCR2. In line with this
hypothesis, the effects of hBD2 in human mo-DC’s as well as in
murine BM-DC’s were completely blocked by a CCR2 inhibitor.
We found a potential interaction between the downstream
signaling molecules of the TLR and CCR signaling pathways.
One possibility is that the signaling molecules NF-κB and
CREB compete for the coactivator CBP. But also other signaling
molecules such as the extracellular signal-regulated kinase (ERK)
that plays an important role in TLR signaling (40) as well as
CCR signaling, by inducing e.g., expression of CCR1 and CCR2
in human monocytic cells may play important roles (41, 42).
Unfortunately, it is not possible to test the CCR2 dependency
of the hBD2 effect in vivo because CCR2−/− mice are protected
from experimental induced colitis (43).
Based on the feasibility of recombinant hBD2 production
(26), negligible toxicity, and strong anti-inflammatory CCR2
dependent modulation of DCs, we hypothesized that hBD2
could be used as a systemic anti-inflammatory biological. This
strategy uncouples the classical intra-intestinal functions of
hBD2 from their potent immunomodulatory capacity, and thus
represents a new paradigm in therapeutic use of antimicrobial
peptides. Indeed, subcutaneously administered hBD2 improved
the outcome of colitis in three different in vivo models of
IBD, namely DSS-, TNBS-, and T-cell transfer-mediated colitis.
This is in line with our observation of hBD2 to rapidly
enter the blood stream after s.c. administration and is likely
mediated by its anti-inflammatory activity on several blood cell
populations, and especially the DC fraction, as described above.
We therefore tested and found that hBD2 administered s.c. could
act as an immune-modulator, attenuating inflammation, that
characterizes IBD. This finding is consistent with the observation
of Aden et al. (44) who studied the development of colitis in IL-
23 receptor deficient mice (Il23R1IEC) and found these to display
decreased levels of leukocyte derived IL-22 and of Reg3b, a C-type
lectin with antimicrobial activity (45). Systemic administration
of Reg3b significantly improved DSS-colitis in Il23R1IEC mice
by recruiting IL-22 secreting neutrophils supporting a protective
role for Reg3b in colitis (44). In addition, the hBD2-induced
wound healing in intestinal epithelial cells in vitro (19) may
add another mechanism of action. Finally, rectally applied
porcine β-defensin 2 (pBD2) has been used for the treatment
of DSS colitis in mice by Han et al. (46). They found pBD2
to be protective against mucosal injury and disruption of the
epithelial barrier associated with DSS colitis. Furthermore, they
reported decreased inflammatory infiltrates and expression of
inflammatory mediators upon treatment with pBD2 as well as
an increase in intestinal tight junction structure and function
compared to untreated DSS control mice. In contrast to the local
administration employed by Han et al., we provide evidence for a
distinct anti-inflammatory effect with systemic application.
Despite ongoing development of therapeutic approaches,
new treatment strategies for the management of IBD are still
urgently needed. Corticosteroids remain the standard therapeutic
options for active CD and UC. However, their beneficial effects
are associated with severe side effects such as osteoporosis,
moon face, mood disturbances, glaucoma, and hypertension
(47). In recent years, several new therapeutics targeting the
molecular mechanisms of intestinal and systemic inflammation
have been developed. Among these, anti-TNFα antibodies have
been the most successful and most commonly used biological
(48). However, primary and secondary lack of response as well
as serious side effects, limits their use. More recently, antibodies
targeting IL-17 in CD and IL-13 in UC have been proposed as
IBD management. Yet, despite promising preclinical data, both
antibodies failed to improve the outcome of CD or UC (49) in
patients. Secukinumab, an anti-IL-17 antibody, even worsened
the disease in a clinical trial in CD patients (50) and two anti-
IL-13 antibodies also failed to produce positive results in clinical
trials for UC (51, 52). This negative effect of IL-17 blockade may
in part be explained by blocking the hBD2 pathway, which is also
mediated by IL-17.
In conclusion, the results presented here constitute the
first in vivo proof of therapeutic efficacy of a systemically
administered human defensin. It is, however, important to stress,
that in all tested models, hBD2 were administered before the
onset of clinical inflammation. We therefore provide strong
evidence for the potential of hBD2 treatment to keep patients
in remission, but studies are warranted to examine if hBD2 also
exhibits treatment efficacy of acute and relapsed inflammation.
The use of natural host defense peptides could provide a
new chapter of effective, minimal-side-effect treatment strategies
of IBD.
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